Limited Anti-Tumor Activity of Combined BET and MEK Inhibition in Neuroblastoma

BACKGROUND: The treatment of high-risk neuroblastoma continues to present a formidable challenge to pediatric oncology. Previous studies have shown that BET (Bromodomain and extra-terminal) inhibitors can inhibit MYCN expression and suppress MYCN-amplified neuroblastoma in vivo. Furthermore, alterat...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Pediatr Blood Cancer
Main Authors: Healy, Jason R., Hart, Lori S., Shazad, Alexander L., Gagliardi, Maria E., Tsang, Matthew, Elias, Jimmy, Ruden, Jacob, Farrel, Alvin, Rokita, Jo Lynne, Li, Yimei, Wyce, Anastasia, Barbash, Olena, Batra, Vandana, Samanta, Minu, Maris, John M., Schnepp, Robert W.
Formato: Artigo
Idioma:Inglês
Publicado: 2020
Assuntos:
Article
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7188563/
https://ncbi.nlm.nih.gov/pubmed/32307821
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/pbc.28267
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares